The Discs Large (DLG) tumour suppressor protein is targeted for ubiquitin mediated degradation by the high risk human papillomavirus (HPV) E6 proteins. In this study we have used a mutational analysis of E6 in order to investigate the mechanism by which this occurs. We ®rst show that the dierences in the anities of HPV-16 and of HPV-18 E6 proteins for binding DLG is re¯ected in their respective abilities to target DLG for degradation. A mutational analysis of HPV-18 E6 has enabled us to de®ne regions within the carboxy terminal half of the protein which are essential for the ability of E6 to direct the degradation of DLG. Mutants within the amino terminal portion of E6 which have lost the ability to bind the E6-AP ubiquitin ligase, as measured by their ability to degrade p53, nonetheless retain the ability to degrade DLG. Signi®cant levels of DLG degradation are also obtained using wheat germ extracts which lack E6-AP. Finally, we show that the transfer of the DLG binding domain onto the low risk HPV-6 E6 confers DLG binding activity to that protein and, most signi®cantly, allows HPV-6 E6 to target DLG for degradation. These results indicate that E6 mediated degradation of DLG does not involve the E6-AP ubiquitin ligase and, in addition, shows that the high and low risk HPV E6 proteins most likely share a common cellular intermediary in the ubiquitin pathway. Oncogene (2000) 19, 719 ± 725.
Introduction
Human Papillomaviruses (HPVs) are the principal aetiological agent of cervical cancer (zur Hausen and Schneider, 1987; zur Hausen, 1991) . The two viral types most frequently found in cervical tumours, HPV-16 and HPV-18, encode two oncoproteins, E6 and E7, which are largely responsible for the viruses' malignant potential. Both E6 and E7 interact with key components of the cellular regulatory machinery, in particular with the tumour suppressor proteins p53 and pRb respectively (Werness et al., 1990; Dyson et al., 1989) . Although both E6 and E7 are retained and continually expressed in cervical tumours and derived cell lines (Schwarz et al., 1985; Smotkin and Wettstein, 1986; Androphy et al., 1987; Banks et al., 1987) , and both will co-operate with cellular oncoproteins in a variety of transformation systems Pim et al., 1994) , there is now growing evidence that it is the E6 protein that contributes most signi®cantly to the malignant potential of the virus (Hiraiwa et al., 1993; Song et al., 1999) . A major feature of the E6 proteins derived from the high-risk virus types is their ability to target cellular proteins for ubiquitin mediated degradation. This was ®rst shown for p53, where the cellular protein E6-AP and E6 together function as an E3 ubiquitin ligase for the degradation of p53 (Werness et al., 1990; Schener et al., 1990; Huibregtse et al., 1991 Huibregtse et al., , 1993 . Although this activity of E6 is likely to play a role during the development of cervical tumours, it is clear that other functions of the E6 proteins are required for malignant progression. Several mutants of E6 have now been described which have lost the ability to interact with p53 but have retained the ability to transform cells (Pim et al., 1994; Ishiwatari et al., 1994; Nakagawa et al., 1995; Inoue et al., 1998) . However, recent studies have de®ned a new cellular target of the high risk E6 proteins, the discs large (DLG) tumour suppressor protein, interaction with which would appear to be absolutely required for E6's transforming activity (Kiyono et al., 1997) .
The DLG protein belongs to a family of proteins called MAGUKs (membrane associated guanylate kinase homologues) (Lue et al., 1994; Muller et al., 1995) . These proteins are characterized by having several PDZ domains, repeated throughout the length of the protein, which function as speci®c protein recognition motifs (Ponting and Phillips, 1995; Saras and Heldin, 1996; Kim, 1997; Kim et al., 1998) . Indeed, it is through interaction with these PDZ domains that the HPV-16 and HPV-18 E6 proteins can interact with DLG (Lee et al., 1997; Kiyono et al., 1997; Gardiol et al., 1999) . Little is known about the functions of the mammalian DLG protein as most of the studies to date have been performed on the Drosophila equivalent. Such studies have shown that knockout of the dlg-1 locus is lethal, and a characteristic of these mutations is uncontrolled cell proliferation and loss of cell polarity (Woods et al., 1996; Goode and Perrimon, 1997) . Mammalian DLG is expressed in a variety of cell types, including epithelia where it has been shown to be located at regions of cell ± cell contact (Lue et al., 1994) , and has been found in complex with the Shaker channel 4.1 protein and the tumour suppressor protein, APC (Kim et al., 1995; Marfatia et al., 1996; Matsumine et al., 1996) . Taking these data together, it is likely that DLG plays an intimate role in the processes that regulate cell polarity and cell growth in response to cell contact.
Recent studies have shown that tumours induced by E6 in transgenic animals are considerably more aggressive than those induced by E7 (Song et al., 1999) . In addition, mutational analysis of E6 indicates that the association with DLG is critical for its transforming activity in rodent cells (Kiyono et al., 1997) . More recently, we have shown that high risk E6 proteins can also target DLG for ubiquitin mediated degradation (Gardiol et al., 1999) . Degradation of p53 by E6 is known to involve the cellular ubiquitin ligase, E6-AP (Huibregtse et al., 1991 ; however it is presently not known how E6 targets DLG for degradation. In order to address this question we have made use of a panel of HPV-18 E6 mutant proteins. We show that the regions of E6 that are required for degradation of DLG are distinct from those required for the degradation of p53. Using a series of chimaeric E6 molecules we have been able to show that the bulk of the activity lies within the carboxy terminal half of the E6 protein. We also show that the last seven amino acids of HPV-18 E6 (which include the DLG binding motif), when fused to the carboxy terminus of the low risk HPV-6 E6, will enable HPV-6 E6 to interact with DLG and, most signi®cantly, will allow HPV-6 E6 to target DLG for degradation. These results demonstrate that the mechanism by which HPV E6 proteins target DLG for degradation most likely does not involve E6-AP. They also show that the E6 proteins from low risk HPV types can also interact with components of the ubiquitin pathway and suggests that their, as yet unidenti®ed, substrate proteins may also be targets for ubiquitin mediated degradation.
Results

HPV-18 E6 binds DLG more strongly than HPV-16 E6
Previous studies had shown that sequences in the extreme carboxy terminus of HPV-16 and HPV-18 E6 were responsible for binding to the PDZ domains of DLG (Lee et al., 1997; Kiyono et al., 1997) . In the case of HPV-16 E6 this appeared to require PDZ domain 2 (Kiyono et al., 1997) , whereas HPV-18 E6 was shown to be capable of binding independently to any of the PDZ domains 1, 2 or 3 (Gardiol et al., 1999) . This dierence was believed to be related to the dierence in the consensus PDZ binding motif between HPV-16 and HPV-18 E6. In order to directly compare the relative binding anities of HPV-16 and HPV-18 E6 proteins for DLG, we ®rst performed a GST pull down assay using GST-DLG and in vitro translated HPV-16 and 18 E6 proteins; GST-p53 was also included for comparison. The results are shown in Figure 1a . It is clear that while HPV-16 E6 binds somewhat more strongly to p53 than HPV-18 E6, which is in agreement with previous observations (Werness et al., 1990; Schener et al., 1990) , HPV-18 E6 binds to DLG signi®cantly more strongly than HPV-16 E6. To determine whether this is re¯ected in their respective abilities to degrade DLG, in vitro and in vivo degradation assays were then performed and the results are shown in Figure 1b ,c respectively. As can be seen in both in vitro and in vivo assays HPV-18 E6 induces signi®cantly greater degradation of DLG than HPV-16 E6. Therefore, these results con®rm the previous supposition that HPV-18 E6 indeed has a stronger anity for DLG than HPV-16 E6, and demonstrate that this is re¯ected in their respective abilities to target DLG for degradation. proteins were used in GST-pull down assays with GST-DLG. GST-NTDLG, which lacks the PDZ binding domains, was used as a negative control and GST-p53 was used as a positive control. The lower panel is the Coomassie stained gel and shows equal levels of GST fusion protein loading for each pair of comparisons. The right-hand panel shows equal levels of input E6 proteins. Percentage recoveries were as follows: GST-NT DLG 51% 16E6 or 18E6; GST-DLG 37% 16E6, 82% 18E6; GST-p53 30% 16E6, 24% 18E6. (b) HPV-18 E6 induces a faster degradation of DLG than HPV-16 E6 in vitro. In vitro translated DLG was incubated, either alone or with HPV-16 or HPV-18 E6 at 308C for 0, 1 or 2 h. The remaining DLG was detected by immunoprecipitation and autoradiography. (c) HPV-18 E6 degrades DLG more eciently than HPV-16 E6 in vivo. U2OS cells were transfected with 3 mg of the DLG expression plasmid together with 0.5, 1 and 3 mg of either the HPV-16 or HPV-18 E6 expression plasmids as indicated. After 24 h cells were harvested and remaining DLG ascertained by Western blot analysis (Crook et al., 1991; Pim et al., 1994; Li and Cono, 1996) . In order to determine whether similar regions of E6 were also involved in the degradation of DLG we made use of a previously characterized panel of HPV-18 E6 mutant proteins (Pim et al., 1994) and these are shown schematically in Figure 2 . Degradation assays were performed both in vitro and in vivo and the results obtained are shown in Figures 3 and 4 respectively. As can be seen, the regions of E6 required for the degradation of DLG encompass large portions of the E6 protein with, in particular, the region from amino acid 101 to amino acid 130, as de®ned by mutants DE, DF and DG, being particularly important both in vitro and in vivo. As can be seen from Figure 2 , these mutations lie well outside the core DLG binding motif which is located at the extreme carboxy terminus of the E6 protein (residues 155 ± 158). Interestingly, mutant DH (D144 ± 149) which lacks six amino acid residues immediately prior to the DLG binding motif, and thus brings the motif closer to the carboxy terminal loop, has no eect on the ability of E6 to degrade DLG, indicating that the spacing between the putative zinc ®nger and the DLG binding domain is not an important aspect of this activity. Most interesting are the results with the three amino terminal mutants of E6: M2 (R10S, P11G), DM (D28 ± 31) and DA (D47 ± 49). Both M2 and DA are defective with respect to their ability to induce p53 degradation (Pim et al., 1994; Gardiol and Banks, 1998 ; see also Figure 5c ), yet both are active with respect to DLG. Although the DA mutant is defective in vitro, it is interesting to note that it is active in vivo, suggesting signi®cant dierences between the two assay systems. This is consistent with previous observations which indicated that this was also the case with p53 degradation assays (Foster et al., 1994; Crook et al., 1996; Gardiol and Banks, 1998) . Signi®cant levels of DLG degradation were also obtained with the DM mutant which has been shown previously to be greatly reduced in its ability to bind E6-AP (Pim and Banks, 1999) . Taken together, these studies demonstrate that the mechanism by which E6 targets DLG for degradation is separate from that used to target p53.
To further investigate any potential role for E6-AP in E6 mediated degradation of DLG we performed in vitro degradation assays using proteins translated in wheat germ extracts which lack any E6-AP (Huibregtse et al., 1991) . The results obtained are shown in Figure  5 . As can be seen, both DLG and p53 are eciently degraded by HPV-18 E6 when translated using rabbit reticulocyte lysate. In contrast, when wheat germ extracts are used, no degradation of p53 is obtained whereas there is still a signi®cant reduction in the levels of DLG. These results further demonstrate that E6 induced degradation of DLG can occur in the absence of E6-AP.
Low risk E6 proteins also target cellular proteins for ubiquitin mediated degradation
To further de®ne the mechanism by which the HPV E6 proteins target DLG for degradation we generated a number of chimaeric E6 proteins. Previous studies had shown that both the amino terminal and carboxy terminal halves of the high risk E6 proteins were required for the degradation of p53 (Crook et al., 1991; Pim et al., 1994; Li and Cono, 1996) . In particular, the use of HPV-6 and HPV-16 E6 chimaeric proteins showed that sequences in the carboxy terminal half of E6 were largely responsible for binding p53, whereas sequences in the amino terminal half of E6 were responsible for degradation (Crook et al., 1991) . However we were particularly interested in determining how these chimaeric proteins would behave with respect to DLG, especially since the HPV-6.16 E6 Figure 3 Mutational analysis of the regions of HPV-18 E6 involved in inducing the degradation of DLG in vitro. In vitro translated DLG was incubated in the presence of the wild type (wt) and mutant HPV-18 E6 proteins for 1 or 2 h as indicated. The remaining DLG was then ascertained by immunoprecipitation followed by SDS ± PAGE and autoradiography. The lower panel shows the inputs of the mutant E6 proteins Figure 4 Mutational analysis of the regions of HPV-18 E6 involved in inducing the degradation of DLG in vivo. U2OS cells were transfected with 3 mg of the DLG expression plasmid together with 3 mg of the wild type (WT) and mutant HPV-18 E6 expression plasmids. After 24 h the cells were harvested and residual DLG ascertained by Western blot analysis. Lane C represents control transfected cells chimaera, which comprises the N-terminal 60 amino acids from HPV-6 E6 and the C-terminal 92 amino acids from HPV-16 E6 (Crook et al., 1991) , should have all the necessary sequences required for binding DLG. We ®rst performed in vivo degradation assays with the HPV-16.6 and HPV-6.16 E6 chimaeric proteins, and the results obtained are shown in Figure  6a . As can be seen, the HPV-16.6 E6 chimaera which comprises the N-terminal 59 amino acids from HPV-16 E6 and the C-terminal 90 amino acids from HPV-6 E6, has only a modest eect on the levels of DLG. In contrast, the HPV-6.16 E6 chimaera is as eective as HPV-16 E6 in targeting DLG for degradation. This is in marked contrast to the eects of these chimaeric proteins on p53 steady state levels which are shown in Figure 6c , where neither protein is capable of degrading p53, and agrees with previous observations (Foster et al., 1994; Li and Cono, 1996) . To further elucidate the mechanism by which DLG was being degraded by E6, we then constructed three smaller chimaeric E6 molecules. These consisted of an HPV-6 E6 backbone with the last 18 amino acids from HPV-18 E6, and the last seven amino acids of HPV-18 E6 or the last eight amino acids of HPV-16 E6 added on to the end of the HPV-6 E6 protein. The reasoning being that, since the HPV-6.16 E6 chimaera could degrade DLG we wished to determine whether the PDZ consensus binding motif alone was sucient to confer binding, and secondly whether low risk E6 proteins had any signi®cant capacity to target cellular proteins for degradation. The results obtained are also shown in Figure 6a and, strikingly, show that addition of just the last seven or eight amino acids of either HPV-18 (6.18 S ) or 16 E6 (6.16 S ) onto the carboxy terminus of HPV-6 E6 results in that protein being capable of degrading DLG in vivo. Addition of a further 12 residues onto HPV-6 E6 from HPV-18 E6 (6.18 L ) did not appear to signi®cantly increase the degradation eciency. Parallel assays were performed on p53 and, as can be seen from Figure 6c , none of these chimaeric proteins could target p53 for degradation. In order to verify that the addition of the last seven amino acids of HPV-18 E6 onto HPV-6 E6 did indeed confer DLG binding activity, we performed a GST pull down assay with in vitro translated DLG. As can be seen from Figure 6b , HPV-6 E6 is completely defective with respect to binding DLG, yet addition of the PDZ binding domain from HPV-18 E6 confers complete binding.
In order to overcome any potential problems associated with dierences in the levels of protein expression in vivo, the degradation assay was performed with HPV-6 E6 and the HPV-6.18 S chimaera in vitro. The results obtained are shown in Figure 7 . As can be seen, Figure 5 Comparison of HPV-18 E6 induced degradation of DLG in rabbit reticulocyte lysate and wheat germ extracts. HPV-18 E6, p53 and DLG were translated in wheat germ extract (WGE) or rabbit reticulocyte lysate (RRL). The proteins were then mixed in the combinations indicated and incubated at 308C for the times shown. The remaining p53 and DLG was ascertained by immunoprecipitation followed by PAGE and autoradiography. The upper panel shows the DLG degradation assay and the lower panel shows the p53 degradation assay a b c Figure 6 Addition of the extreme carboxy terminal region of HPV-18 E6 onto HPV-6 E6 confers DLG binding and degradation. (a) U20S cells were transfected with 3 mg DLG expression plasmid together with 3 mg of either the wild type or chimaeric E6 expression plasmids as indicated. After 24 h the cells were harvested and residual DLG was ascertained by Western blot analysis. (b) GST pull down assay of in vitro translated DLG with HPV-6 E6, HPV-18 E6, HPV-6.18 L (HPV-6 E6 plus the carboxy terminal 19 amino acids of HPV-18 E6) and HPV-6.18 S (HPV-6 E6 plus the carboxy terminal 7 amino acids of HPV-18 E6) GST fusion proteins as indicated. Bound DLG was ascertained by SDS ± PAGE and autoradiography. The upper panel shows the Coomassie stain of the same gel and shows equal levels of loading of the HPV-6 E6 based GST fusion proteins. (c) Saos-2 cells were transfected with 4 mg of p53 expression plasmid together with 5 mg of the indicated E6 expression plasmids. After 24 h the cells were harvested and remaining p53 ascertained by Western blot analysis HPV-6 E6 has no eect upon DLG levels over the course of the assay whereas the HPV-6.18 S chimaera induces almost complete degradation of DLG over the same period of time. Taken together, these results demonstrate that the low risk HPV E6 proteins also interact with a component of the ubiquitin pathway and can be induced to bring about the degradation of a cellular target protein. Since these low risk HPV E6 proteins only have a very low anity for E6-AP (Schener et al., 1990 , this activity must be mediated by another, as yet unknown, ubiquitin ligase and this points to another potential target for therapeutic intervention in HPV induced disease.
Discussion
The DLG tumour suppressor protein is intimately involved in processes regulating cell growth in response to external stimuli and cell contact. The demonstration that DLG is regulated by the ubiquitin pathway, which in turn can be used by the high risk E6 proteins, has important implications for the role of this interaction in the development of cervical cancer (Gardiol et al., 1999) . In this study we have continued to investigate the mechanism by which E6 induces the degradation of DLG. We show that this activity of E6 is independent of its association with p53 and rule out a direct involvement of the E3 ubiquitin ligase, E6-AP. Rather, the demonstration that the low risk E6 proteins can also target DLG for degradation following the addition of a binding site, together with the demonstration that HPV-18 E6 can degrade DLG in wheat germ extracts, indicates the involvement of another, as yet unknown ligase.
Previous studies had suggested that the mechanism of interaction between HPV-16 and HPV-18 E6 proteins with DLG was somewhat dierent. HPV-16 E6 was reported to require PDZ domain 2 on DLG (Kiyono et al., 1997) , whereas HPV-18 E6 was shown to bind independently to PDZ domains 1, 2 or 3 (Gardiol et al., 1999) ; although dierent assay systems were used in these two studies. Preliminary studies had also suggested that HPV-18 E6 could more readily target DLG for degradation in vivo (Gardiol et al., 1999) . In order to verify whether this was indeed the case, a series of comparative binding assays were performed which showed that HPV-18 E6 does indeed bind DLG more strongly than HPV-16 E6. This increased level of interaction is also re¯ected in a higher level of induced degradation both in vitro and in vivo. This contrasts markedly with the E6-p53 interaction where HPV-16 E6 has consistently been shown to bind and degrade p53 more eectively than HPV-18 E6 (Werness et al., 1990; Schener et al., 1990) . It is interesting at this point to speculate whether the increased activity of HPV-18 with respect to DLG may be re¯ected in any pathological outcomes of infection. Certainly, there is an extensive literature which indicates that HPV-18 is generally more active than HPV-16 in a variety of transformation assays (Barbosa and Schlegel, 1989; Villa and Schlegel, 1991) . In addition, there are also several reports which indicate that HPV-18-containing cervical tumours have a more aggressive phenotype and are also more prone to recurrence than HPV-16-containing tumours (Barnes et al., 1988; Kurman et al., 1988; Burnett et al., 1992; Zhang et al., 1995) . Since the only biochemical activity of HPV-18 which correlates with this trend, so far, is the increased activity of E6 with respect to DLG, it is tempting to speculate that it is this association which is critical for the malignant progression of HPV induced tumours.
HPV E6 induced degradation of p53 requires the interaction with the cellular ubiquitin ligase E6-AP (Huibregtse et al., 1991 . Extensive mutational analysis of E6 indicates that this binds to the amino terminal region of the E6 protein and that only the E6 proteins of high risk HPV types can interact to any signi®cant degree (Huibregtse et al., 1991; Pim et al., 1997) . In this study we have used a well-de®ned panel of E6 mutants (Pim et al., 1994; Pim and Banks, 1999) to investigate the requirements for E6 induced degradation of DLG. It is clear that sequences that are essential for p53 degradation, as de®ned by mutants M2 (R10S, P11G), DM (D28 ± 31) and DA (D47 ± 49) which lie within the amino terminal half of the E6 protein, are largely dispensable for the degradation of DLG. This broadly covers the region of E6 which is required for high anity binding to p53 via E6-AP (Li and Cono, 1996) and is the ®rst line of evidence that suggests that E6-AP is not involved in the degradation of DLG. In contrast, mutants within the carboxy terminal half of E6, which had previously been shown to be involved in basic binding to p53 (Crook et al., 1991; Li and Cono, 1996) , as de®ned by mutants DE (D101 ± 104), DF (D113 ± 117) and DG (D126 ± 130), were however found to be required for E6 induced degradation of DLG, again suggesting a lack of E6-AP involvement. It should be emphasized that these mutants are well clear of the DLG binding motif located at residues 155 ± 158. In addition, it is worth noting that the DH (144 ± 149) mutation, although much closer to the DLG binding site, has no deleterious eect upon E6 induced degradation of Figure 7 HPV-6.18 S induced degradation of DLG in vitro. In vitro translated DLG was incubated, either alone or with HPV-18 E6, HPV-6 E6 or the HPV-6.18 S chimaera at 308C for 0, 1 or 2 h as indicated. The remaining DLG was detected by immunoprecipitation and autoradiography. The lower panel shows the inputs of the E6 proteins used DLG. Further evidence for a lack of E6-AP involvement also comes from the degradation assays performed in the wheat germ extract. This system lacks any E6-AP (Huibregtse et al., 1991) , yet HPV-18 E6 is still capable of inducing DLG degradation, albeit not as eciently as in the rabbit reticulocyte lysate. This is in marked contrast to p53, where no degradation is obtained in the wheat germ system. Obviously we cannot formally rule out a role for E6-AP in vivo, however the above results strongly suggest the involvement of at least one other as yet unknown, ubiquitin ligase in E6 mediated degradation of DLG.
We then proceeded to investigate the potential of low risk HPV E6 proteins to interact with the ubiquitin pathway by the use of a chimaeric analysis, a summary of which is shown in Figure 8 . Clearly the HPV-6.16 E6 chimaera is capable of directing DLG degradation but the HPV-16.6 E6 chimaera is not; this however could merely be a re¯ection of lack of binding to DLG with the 16.6 E6 protein. However, addition of just seven amino acids from the carboxy terminus of HPV-18 E6 onto the carboxy terminus of HPV-6 E6 allows that protein to bind DLG. Most strikingly, the HPV-6.18s E6 chimaera can then target DLG for degradation. Since HPV-6 E6 is reported to be largely defective for binding E6-AP this would also appear to rule out any involvement of E6-AP in E6 mediated degradation of DLG. The second important point to be taken from these studies is that this demonstrates that the low risk HPV E6 proteins will also interact with a component of the ubiquitin system. It seems extremely likely that this is the same protein that is being used by the high risk E6 proteins to degrade DLG. It now remains to be determined whether this ligase is also responsible for regulating DLG levels in the absence of E6, and which cellular proteins are normally targeted by the low risk viral E6 proteins.
Materials and methods
Cells and tissue culture
Human Saos-2 and U2OS cells were grown in DMEM with 10% foetal calf serum. All the transfections were carried out using the calcium phosphate precipitiation procedure, as described previously , and transfection eciencies were monitored by performing parallel b-galactosidase assays.
Plasmids
Plasmids for expressing DLG in vivo and in vitro have been described previously (Lee et al., 1997; Gardiol et al., 1999) . For GST fusion protein production, DLG and NT-DLG were cloned into pGEX 2 and have also been described previously (Lee et al., 1997; Gardiol et al., 1999) .
The HPV-18 E6 mutants used in this study were DNT (D4 ± 7), M2 (R10S, P11G), DM (D28 ± 31)), DA (D47 ± 49), DE (D101 ± 104), DF (D113 ± 117), DG (D126 ± 130) and DH (D144 ± 149) and have been described previously (Pim et al., 1994; Pim and Banks, 1999) . The wild type and mutant E6s were cloned into pSP64 for in vitro expression and into pCDNA3 for in vivo expression (Pim et al., 1994; Gardiol and Banks, 1998) . The two chimaeric constructs, HPV-16.6 E6 and HPV-6.16 E6 have been described previously (Crook et al., 1991) , but were subcloned into pCDNA-3 for this study. The HPV-6.18 L , HPV-6.18 S and HPV-6.16 S chimaeras (shown schematically in Figure 7 ) were produced by PCR ampli®cation and cloned into pCDNA-3 and pGEX-2T and were veri®ed by DNA sequencing.
GST fusion protein binding assays
The in vitro binding assays were performed as described previously (Thomas et al., 1995; Gardiol et al., 1999) , and bound proteins were washed extensively in PBS containing 1% NP40 before analysing on SDS ± PAGE and autoradiography.
Degradation assays
For the in vitro assays, proteins were translated using either the TNT coupled rabbit reticulocyte lysate or wheat germ extract systems (Promega) as indicated in the text according to the manufacturer's instructions, in the presence of [ 35 S]-cysteine. The translated E6 proteins were then quantitated by PhosphoImager analysis, and equal amounts of wild type and mutant E6 proteins were added to a constant amount of in vitro translated DLG. Following incubation of the E6 proteins with DLG for 1 or 2 h, the remaining DLG was assessed by immunoprecipitation with an antibody raised against the GST-NT.DLG fusion protein (Lee et al., 1997) , followed by SDS ± PAGE and autoradiography. The in vivo degradation assays for p53 and DLG were performed as described previously (Gardiol and Banks, 1998; Gardiol et al., 1999) . 
